• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Novel therapies for the treatment of small-cell lung cancer: a time for cautious optimism?

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Board, Ruth E
    Thatcher, Nick
    Lorigan, Paul C
    Affiliation
    Cancer Research UK Department Medical Oncology, Christie Hospital, Manchester, UK. Ruth.Board@christie-tr.nwest.nhs.uk
    Issue Date
    2006
    
    Metadata
    Show full item record
    Abstract
    Small-cell lung cancer accounts for up to one-fifth of all lung cancers diagnosed. While the response rates to chemotherapy are high, ultimately the majority of patients will relapse and die from their disease. Long-term outcomes are poor. A number of new agents and novel strategies for the treatment of small-cell lung cancer are under evaluation, and this review outlines the current most promising agents and pivotal trials. Oblimersen, an antisense oligonuclide to the oncogene bcl-2, has been safely combined with chemotherapy. The proteosome inhibitor bortezomib has not demonstrated single-agent activity in phase II trials but is now being evaluated with proapoptotic triggers. A number of anti-angiogenic strategies have been evaluated in small-cell lung cancer. The vascular endothelial growth factor (VEGF) antibody bevacizumab and a number of VEGF receptor tyrosine kinase inhibitors are in the early phases of clinical trials. Results from trials have not demonstrated any survival advantage with the addition of matrix metalloproteinase inhibitors. A phase III trial has reported improvements in median survival with the addition of thalidomide to chemotherapy, but toxicity has been problematic. Immunotherapy with p53 vaccines and BEC2 antibodies have shown some promise and require further evaluation to determine whether humoral responses can predict for response. Trials with the immunoconjugate BB-10901 and temirolimus are ongoing.
    Citation
    Novel therapies for the treatment of small-cell lung cancer: a time for cautious optimism? 2006, 66 (15):1919-31 Drugs
    Journal
    Drugs
    URI
    http://hdl.handle.net/10541/72643
    PubMed ID
    17100404
    Type
    Article
    Language
    en
    ISSN
    0012-6667
    Collections
    All Christie Publications

    entitlement

    Related articles

    • The role of new targeted therapies in small-cell lung cancer.
    • Authors: Rossi A, Maione P, Colantuoni G, Guerriero C, Gridelli C
    • Issue date: 2004 Jul
    • The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    • Authors: Langer CJ, Natale RB
    • Issue date: 2005 Dec
    • Small cell lung cancer and targeted therapies.
    • Authors: Blackhall FH, Shepherd FA
    • Issue date: 2007 Mar
    • Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    • Issue date: 2007
    • New antiangiogenetic agents and non-small cell lung cancer.
    • Authors: Gridelli C, Rossi A, Maione P
    • Issue date: 2006 Oct
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.